Free Trial
NASDAQ:STOK

Stoke Therapeutics Q4 2023 Earnings Report

Stoke Therapeutics logo
$7.69 +0.13 (+1.72%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$7.30 -0.39 (-5.01%)
As of 04/17/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.62
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Stoke Therapeutics Revenue Results

Actual Revenue
$2.80 million
Expected Revenue
$3.70 million
Beat/Miss
Missed by -$900.00 thousand
YoY Revenue Growth
N/A

Stoke Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 25, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Stoke Therapeutics' Q1 2025 earnings is scheduled for Monday, May 5, 2025, with a conference call scheduled on Tuesday, May 6, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Stoke Therapeutics Earnings Headlines

FY2029 EPS Estimate for Stoke Therapeutics Raised by Analyst
‘Wheels Are Falling Off’ the U.S. Stock Market
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK)
See More Stoke Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email.

About Stoke Therapeutics

Stoke Therapeutics (NASDAQ:STOK), an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

View Stoke Therapeutics Profile

More Earnings Resources from MarketBeat